Macrolide antibiotics are macrocyclic compounds that contain one or two sugars in their structure. Almost all macrolide antibiotics that are curently used in clinics are derivatives of naturally isolated macrolides from plants, fungi, actinobacteria and insects. Numerous macrolide derivatives are reported so far in the literature but clinically most significant macrolides are those having a 14-, 15- or 16- membered macrocyclic ring. Macrolides have generally shown a wide range of biological activity, such as anti-inflammatory, immunomodulary, antifungal, antiparasitic and antitumor, but the most pronounced is definitely antibacterial activity. Macrolide antibiotics exert their antimicrobial activity through binding within the peptide exit tunnel of the bacterial 50S ribosomal subunit peptide and interfering with bacterial protein synthesis. In addition to bacterial activity, macrolides have also shown to be clinically useful in fighting virus pathogens. For example, azithromycin showed in vitro antiviral activity against Zika and Rhino viruses. Thus, azithromycin has become interesting in assessing its potential to treat infections caused by SARs-CoV-2 coronavirus. Although the antiviral acitivity of azithromycin against SARs-CoV-2 coronavirus has not been confirmed, there are indications that it may be effective in combination with hydroxychloroquine. In this paper, we tried to prepare a new structuraly unique macrolide derivative (27) by introducing a glucose to a N(9a) position of the macrocyclic ring using the reaction of transamidation of a macrolide derivative (24) containing an aminopropyl chain and a glucose derivative (26) with an incorporated amide group.